Research programme: glycogen synthase kinase 3 inhibitors - Kinetek
Alternative Names: Research programme: GSK-3 inhibitors - KinetekLatest Information Update: 18 Aug 2006
At a glance
- Originator Kinetek Pharmaceuticals
- Class Small molecules
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 31 Dec 2005 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
- 02 Apr 2004 Kinetek Pharmaceuticals has been acquired by QLT
- 23 Aug 2000 Preclinical development for Cancer in Canada (Unknown route)